Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
Clinical trial NCT04887831 · TERMINATED
Trial details
- NCT number
- NCT04887831
- Sponsor
- G1 Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-04
- Primary completion
- 2023-04-07
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.